{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-22-020811","form_type":"8-K","ticker":"AUPH","cik":"0001600620","company_name":"Aurinia Pharmaceuticals Inc.","filed_at":"2022-08-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.320629+00:00","generated_at":"2026-06-24T04:09:01.466499+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Aurinia Q2 2022 revenue up to $28.2M; net loss narrows to $0.25/share","bullets":["Q2 net product revenue $28.2M vs $6.6M YoY; six month revenue $49.8M.","Net loss $35.5M ($0.25/share) vs $47.0M ($0.37) in Q2 2021.","LUPKYNIS patients on treatment ~1,274 at June 30, up 19% from Q1 2022.","2022 net revenue guidance reaffirmed at $115-$135M.","Positive CHMP opinion in Europe; EC decision expected by end of Q3 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-22-020811","json":"https://secwatch.observer/filing/0001628280-22-020811.json","markdown":"https://secwatch.observer/filing/0001628280-22-020811.md","text":"https://secwatch.observer/filing/0001628280-22-020811.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1600620/000162828022020811/0001628280-22-020811-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1600620/000162828022020811/auph-20220804.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T04:09:01.466499+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}